Neurocrine Biosciences reported $1.2M in Interest Expense on Debt for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Interest Expense On Debt Change
ALKERMES ALKS:US USD 3.55M 1.18M
Alnylam Pharmaceuticals ALNY:US USD 41.08M 1.52M
Amgen AMGN:US USD 368M 40M
Biogen BIIB:US USD 59.9M 5.9M
Biomarin Pharmaceutical BMRN:US USD 4.68M 820K
Cytokinetics CYTK:US USD 6.8M 4M
Gilead Sciences GILD:US USD 229M 13M
Halozyme Therapeutics HALO:US USD 7.51M 4.41M
Intercept Pharmaceuticals ICPT:US USD 5.24M 1.43M
IONIS PHARMACEUT IONS:US USD 2.14M 9K
Nektar Therapeutics NKTR:US USD 6.95M 275K
Neurocrine Biosciences NBIX:US USD 1.2M 1000K
Pfizer PFE:US USD 311M 18M
Regeneron Pharmaceuticals REGN:US USD 15.3M 2.2M
Repligen RGEN:US USD 329K 58K
Sarepta Therapeutics SRPT:US USD 14.74M 1.29M
Teva Pharmaceutical TEVA:IT USD 230M 5M
Vertex Pharmaceuticals VRTX:US USD 13.7M 900K
YTE INCY:US USD 641K 37K